Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Stage IIIC, IIID, or IV melanoma that cannot be removed by surgery or has spread to other parts of the body, or Stage III or IV non-small cell lung cancer (NSCLC).
• People with melanoma whose cancer has continued to grow within 12 weeks of stopping a specific type of immunotherapy (anti-PD-1/PD-L1), and who have also received a targeted treatment (BRAF/MEK inhibitor) if their tumour has a BRAF gene mutation.
• People with NSCLC who have received no more than 3 previous cancer treatments, and whose cancer has either grown within 12 weeks of stopping immunotherapy (anti-PD-1/PD-L1), or — for those with a specific gene-driven tumour — has grown during or after at least one targeted therapy and/or chemotherapy.
• People who are in relatively good general health and are able to carry out daily activities with little or no limitation (known as ECOG performance status 0 or 1).
• People who have at least one tumour that surgeons assess as being able to be removed.
• People who still have at least one measurable tumour remaining after one lesion is removed for the trial treatment preparation.
• People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's health requirements.
• People who are willing to complete required heart function tests, and possibly lung function tests if needed.
• People who are able to have children, or whose partners are able to have children, and who are willing to use a reliable form of contraception during treatment and for up to 12 months afterwards.
• People over 70 years of age may be considered for the trial after a discussion between the treating doctor and the trial's medical oversight team (confirm with trial site).

Who may not be able to join:

• People whose melanoma started in the eye (uveal or ocular melanoma).
• People who have brain metastases (cancer that has spread to the brain) that are causing symptoms and have not yet been treated.
• People who have had an organ transplant from another person, or any cell-based therapy that involved preparatory chemotherapy, within the past 20 years.
• People who require ongoing steroid medication at a dose of 10 mg per day of prednisone or an equivalent steroid.
• People who have a condition where their immune system does not work properly from birth or by nature (primary immunodeficiency).
• People who have been diagnosed with another separate cancer within the past 3 years.
• People who have received, or are due to receive, a live or weakened live vaccine within 28 days before starting the trial's preparatory treatment phase.

Important: Always verify eligibility with the trial site directly before applying.